Company overview
Basic information
Company name
Kaušis, MB
Company code
305125562
Registered address
Vilniaus r. sav., Maišiagalos sen., Kalikstiškių vs., Ąžuolų 1-oji g. 19, LT-14249
Registration date
2019-04-11
Company age: 7 y. 6 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Other site preparation
Ownership form
Private without foreign capital
MB "Kaušis"
Company code: 305125562
Address: Vilniaus r. sav., Maišiagalos sen., Kalikstiškių vs., Ąžuolų 1-oji g. 19, LT-14249
Description
This description was generated by artificial intelligence.
Kaušis, MB (company code 305125562) is an operational private small partnership registered in 2019. It belongs to the sector of national private non-financial companies and is described as privately owned, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. Governance is structured as CEO only, and the company is classified as micro. Its registered address is Ažuolu 1-oji g. 19, Kalikstiškiu vs., Maišiagalos sen., Vilniaus r. sav., Vilniaus apskr., LT-14249. The company’s activity is recorded under EVRK code F.43.12.90, Other site preparation works. Financially, the latest financial year available is 2025, when revenue amounted to €13.3K and net profit was -€738, resulting in a -5.6% profit margin. Revenue declined by 6.4% year on year and by 15.9% over two years. Equity stood at €15.4K, total assets at €15.4K, and liabilities were €20. The company’s equity ratio was 99.9% and asset turnover 0.86x. Earlier results show €15.8K revenue and €7.5K net profit in 2023, followed by €14.2K revenue and €795 profit in 2024.
Download a detailed company report
Make confident decisions with all the information about Kaušis, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.